Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients (Jan 2022)
Alterations in genetic and protein content of swine adipose tissue-derived mesenchymal stem cells in the Metabolic Syndrome (May 2019)